Margins inflect sharply; three new profit centers loading for FY28
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade B
H1 EBITDA margin at 17.6% beat 17% guidance; FY27 ₹750 Cr target on track (H1 ₹376 Cr); gross margin guidance >45% delivered 47.5%. But FY28 drivers unmonetized (Prathyak revenue pending, Adelaide TGA deferred).
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong H1 execution ahead of FY27 guidance (₹376 Cr, 17.6% EBITDA margin vs. ₹750 Cr, 17% target). Gross margin expanded sharply to 47.5% (from 40.9% Q1) on inventory management; Australia OTC contracts renewed and expanded (AUD232M term). FY28 inflection credible: Unit III (81% ramp, Dec 2026), Prathyak R&D (Q4 FY27), Adelaide factory (TGA pending Q2 2027). Key risk: Prathyak revenue unquantified and delayed (cost center now, revenue from Q4 FY27 only); Adelaide TGA inspection may slip further; debt at ₹357 Cr expected to peak FY26, decline from FY28 onward.
₹194.9 Cr
Revenue · +null% YoY₹10.5 Cr
Reported PAT · +null% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Gross margin hero; raw material cost fell 3% despite 9% revenue growth
METGross margin 47.5% (up from 40.9% Q1), OPM 20.6%, inventory management drove RM cost down
H1 ahead of plan; EBITDA margin already at 17.6%, beating 17% guidance
METH1 EBITDA margin 17.6% on INR376 Cr revenue (>50% of ₹750 target); 17% guided, matched/beaten
PAT grew 33% QoQ; profit before tax holding steady despite D&A spike
METPAT up 32.7% QoQ to ₹10.5 Cr; D&A rose to ₹25.1 Cr (new capex impact), PBT INR9.9 Cr stable
Unit III ramping complete, Adelaide commissioned Jan 2027 (now slightly delayed)
METUnit III starts Dec 2026, ramping Q4+; Adelaide: Jan 2027 target (pushed from baseline due to Iran logistics), TGA Q2 2027
Prathyak to generate own revenue from Q4 FY27
OVERSTATEDCurrently non-revenue model (cost center), discussions with clients ongoing; no revenue yet; management deferred FY28 guidance
Earnings quality
What changed since the last call
H1 EBITDA margin delivery vs. guidance
UpgradeDelivered 17.6% vs. 17% guidance; inventory management and gross margin expansion drove beat
Australia OTC supply contracts
UpgradeBoth 7.5-year EBOS (AUD202M) and 3-year Wesfarmers (AUD30M) renewed with expanded product portfolio and higher value than predecessors
Receivables working capital impact
DowngradeSpiked to ₹250 Cr (vs. typical 120-day cycle); timing-driven but absorbs cash in H1; expected to normalize Q3-Q4
Prathyak revenue timing
NeutralStill described as 'non-revenue model' under development; Q4 FY27 target for external R&D contracts, but no revenue booked yet; management deferred guidance to next call
Adelaide facility commissioning
NeutralSlipped from original Jan 2027 baseline; now expected Jan 2027 (same), TGA Q2 2027 (slippage visible). Iran logistics cited.
The Q&A
Moderate. Analysts pressed on margin sustainability (Heet, Axis), receivables (Amol Rao, Plutus), Prathyak revenue timing (Murali), and cash flow cyclicality (Gopal Bhatt). Management held firm on ₹750 Cr FY27 target, defended >45% gross margin, but deferred FY28 specifics to next call (January 2027). No one question was dodged outright, but Prathyak revenue guidance was deferred rather than estimated, signaling caution.
Margin sustainability — Heet, Axis Capital
PartialGross margin to stay >45%. Q2 was inventory hero (cleared high-cost prior-quarter stock); ongoing RM recovery plus new capacity ramping (Unit III, Adelaide) will sustain. No quantified sales growth guidance for near-term.
Receivables surge — Amol Rao, Plutus Wealth
AnsweredExport receivables <120 days, domestic 120-150 days. End-of-quarter sales bunching; will normalize Q3-Q4. One-off timing, not a trend.
Philippines contract clarity — Amol Rao
AnsweredTwo separate contracts. USD11M is anti-TB (government program, specific requirement), USD14M is regular business (signed pre-IPO). 11 molecules added this quarter; USD11M and USD14M are distinct.
Prathyak revenue potential — Amol Rao
DodgedToo early to give numbers. Currently cost center; R&D development spend ongoing. Will transition to revenue model from Q4 FY27 onward as external contracts start. Next call will have guidance.
US FDA strategy — Murali (analyst name withheld in transcript)
AnsweredEU GMP and Southeast Asia, Latin America, Middle East focus for 2-3 years. US FDA launch at least 2-3 years out. But keeping option open if CMO client demands own manufacturing; flexible to local market needs.
FY28 guidance — Murali
DodgedToo pre-emptive to give FY28 numbers now. Will release in next earnings call (January–February 2027). Probably the next three years will have substantial increases, but official guidance next call.
Cash flow cyclicality — Gopal Bhatt, Baroda BNP Paribas
AnsweredH1 FY26 was standalone (Noumed not consolidated). This year has 4 subsidiaries, different picture. IPO cash on books (₹110–113 Cr). OFS used for capex. Cash will normalize by year-end; major outflows are CapEx which are tracked separately.
Three-year strategy — Bhavika Singhvi, Niveshaay
AnsweredThree-year vision: Saicriti facility with 154M capacity, backward integration for all dosages, new molecule capabilities (mAbs, biosimilars from 2027–28). All dosages, all geographies, but challenges are project integration and management scaling. Targeting 2030 for full integration; 30 years CDMO experience gives confidence but complexity is real.
Guidance
FY27 INR750 Cr full-year (H1:H2 split 45:55)
HighH1 achieved INR376 Cr (50% of target, exceeding 45% split). H2 needs ₹374 Cr; management says 'very, very comfortably crossing that.' On track.
EBITDA margin 17% maintained for FY27
HighH1 EBITDA margin 17.6%, exceeding 17% guidance. Driven by gross margin expansion and operational leverage.
Gross margin >45% (moderate level, next quarters)
HighQ2 delivered 47.5%; management expects to hold >45% as inventory normalization continues and Unit III/Adelaide ramp.
Saicriti Pharma INR215 Cr total project cost
HighSai contribution INR83.83 Cr (already invested INR15 Cr in Prathyak, INR98.8 more in Saicriti); facility on track for Jul 2027 completion
Adelaide facility AUD46 Cr invested, AUD20 Cr grant received
MediumCommissioning delayed to Jan 2027 (from baseline); TGA inspection Q2 2027. Iran logistics caused initial slip.
Risks the call surfaced
Regulatory & TGA delays
HighSaicriti completion (Jul 2027) and Adelaide TGA inspection (Q2 2027) are path-to-revenue for new capacity. Delays push profitability upside into FY29. Iran logistics has already caused one slip.
Prathyak revenue unmonetized
HighPrathyak Labs (60% stake acquired 15 Sep 2026) currently a cost center. External R&D revenue model promised from Q4 FY27, but no contracts booked yet. Management deferred FY28 revenue guidance, signaling caution. If external clients don't materialize, CapEx spent on R&D assets may not yield returns.
Working capital pressure
MediumReceivables spiked to ₹250 Cr (Q2), up from implied ~₹160 Cr (Q1, 30 days). Management attributes to end-of-quarter timing, expects normalization by Q4. But if export/institutional customers delay payments, OCF could turn negative despite strong profitability.
Debt servicing & leverage
MediumDebt at ₹357 Cr (Sept 2026), up from ₹320 Cr (March 2026). Management expects FY26 to be peak debt year, with decline from FY28 onward as new facilities generate EBITDA. Execution risk if margin expansion stalls or capex delays push debt repayment into FY28+. Current D/E ratio not disclosed.
Australia manufacturing transition risk
MediumAdelaide facility will move Noumed outsourced volumes in-house from Q1 FY28, converting distribution margin to manufacturing margin (higher upside, but execution risk). Australia accounts for 76% of export revenue. TGA inspection deferred to Q2 2027. Any delays in commissioning or regulatory approval could disrupt Australia supply and margin expansion narrative.
Management
Score 8/10. Clear, granular on capex and contract details (Mark Thulborne gave specific AUD values, timelines). Anil Kumar defensive on FY28 guidance ('too pre-emptive'), deferring to next call. Acknowledged execution challenges (Iran logistics, integration complexity) without sugar-coating. H1 EBITDA margin at 17.6% beat 17% guidance; gross margin expanded 660 bps (inventory mgmt). H1 revenue ₹376 Cr on track for ₹750 Cr FY27 target. Capex visible and advancing (Saicriti, Unit III, Adelaide). Noumed consolidation integrated by Q2. Track record: B+ (on-track delivery, no prior misses cited, but new capex still in construction phase).
1 · Dec 2026
Unit III Bhongir ramp-up begins; 81% capacity increase
2 · Q4 FY27 (Jan–Mar 2027)
Prathyak Labs begins external R&D revenue; Saicriti on track for Jul 2027 completion
3 · Jan 2027
Adelaide factory commissioned (TGA inspection Q2 2027); Australia outsourced volumes move in-house
Key risk: Prathyak revenue unquantified and delayed (cost center now, revenue from Q4 FY27 only); Adelaide TGA inspection may slip further; debt at ₹357 Cr expected to peak FY26, decline from FY28 onward.
Informational and educational content only. Not investment advice.